HBC Stock Overview
Hofseth BioCare ASA engages in providing value added biomarine ingredients for human and animal applications in Norway and internationally.
Hofseth BioCare Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||kr3.89|
|52 Week High||kr8.28|
|52 Week Low||kr3.55|
|1 Month Change||-9.11%|
|3 Month Change||-27.96%|
|1 Year Change||-48.13%|
|3 Year Change||49.61%|
|5 Year Change||128.82%|
|Change since IPO||-22.20%|
Recent News & Updates
Health Check: How Prudently Does Hofseth BioCare (OB:HBC) Use Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
|HBC||NO Biotechs||NO Market|
Return vs Industry: HBC matched the Norwegian Biotechs industry which returned -47.8% over the past year.
Return vs Market: HBC underperformed the Norwegian Market which returned 12.3% over the past year.
|HBC Average Weekly Movement||7.6%|
|Biotechs Industry Average Movement||8.3%|
|Market Average Movement||7.3%|
|10% most volatile stocks in NO Market||13.0%|
|10% least volatile stocks in NO Market||4.1%|
Stable Share Price: HBC is not significantly more volatile than the rest of Norwegian stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: HBC's weekly volatility (8%) has been stable over the past year.
About the Company
Hofseth BioCare ASA engages in providing value added biomarine ingredients for human and animal applications in Norway and internationally. Its products include Brilliant salmon oil; OmeGo salmon oil for the maintenance of healthy cholesterol and cardiovascular function; ProGo, a salmon protein hydrolysate powder used as a fast absorbing protein supplement; CalGo, a marine calcium powder produced to support cartilage function and joint health; CollaGo, a collagen peptide powder to enhance the beauty of hair, skin, and nails; and PetGo, a non-soluble protein. The company distributes its products through distributors, agents, and its own sales force.
Hofseth BioCare Fundamentals Summary
|HBC fundamental statistics|
Is HBC overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|HBC income statement (TTM)|
|Cost of Revenue||kr87.53m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
Aug 26, 2022
|Earnings per share (EPS)||-0.38|
|Net Profit Margin||-133.20%|
How did HBC perform over the long term?See historical performance and comparison
Is Hofseth BioCare undervalued compared to its fair value and its price relative to the market?
Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate HBC's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate HBC's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: HBC is unprofitable, so we can't compare its PE Ratio to the European Biotechs industry average.
PE vs Market: HBC is unprofitable, so we can't compare its PE Ratio to the Norwegian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate HBC's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: HBC is overvalued based on its PB Ratio (12.8x) compared to the NO Biotechs industry average (4x).
How is Hofseth BioCare forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Hofseth BioCare has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Hofseth BioCare performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: HBC is currently unprofitable.
Growing Profit Margin: HBC is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: HBC is unprofitable, and losses have increased over the past 5 years at a rate of 18.4% per year.
Accelerating Growth: Unable to compare HBC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: HBC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-6.2%).
Return on Equity
High ROE: HBC has a negative Return on Equity (-125.25%), as it is currently unprofitable.
How is Hofseth BioCare's financial position?
Financial Health Score1/6
Financial Health Score 1/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: HBC's short term assets (NOK154.9M) do not cover its short term liabilities (NOK168.9M).
Long Term Liabilities: HBC's short term assets (NOK154.9M) exceed its long term liabilities (NOK121.0M).
Debt to Equity History and Analysis
Debt Level: HBC's net debt to equity ratio (97.2%) is considered high.
Reducing Debt: HBC's debt to equity ratio has increased from 60.6% to 125.5% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: HBC has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: HBC has less than a year of cash runway if free cash flow continues to reduce at historical rates of 14% each year
What is Hofseth BioCare current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate HBC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate HBC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if HBC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if HBC's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as HBC has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Roger Hofseth (47 yo)
Mr. Roger Hofseth has been the Chief Executive Officer of Hofseth BioCare ASA since August 14, 2017. He is Director at Aqua Bio Technology ASA since January 9, 2019. Mr. Hofseth serves as the Chief Executi...
CEO Compensation Analysis
Compensation vs Market: Insufficient data to establish whether Roger's total compensation is reasonable compared to companies of similar size in the Norwegian market.
Compensation vs Earnings: Roger's compensation has been consistent with company performance over the past year.
Experienced Management: HBC's management team is considered experienced (4.9 years average tenure).
Experienced Board: HBC's board of directors are considered experienced (5.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: HBC insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Hofseth BioCare ASA's employee growth, exchange listings and data sources
- Name: Hofseth BioCare ASA
- Ticker: HBC
- Exchange: OB
- Founded: 2000
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: kr1.392b
- Shares outstanding: 357.83m
- Website: https://www.hofsethbiocare.no
Number of Employees
- Hofseth BioCare ASA
- Kipervikgata 13
- Møre og Romsdal
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/23 00:00|
|End of Day Share Price||2022/05/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.